Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardent Health, Inc. (NYSE: ARDT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ardent Health is a healthcare company in the medical care facilities industry that operates 30 acute care hospitals and approximately 280 sites of care across six states, and its filings offer detailed information on its financial condition, capital structure, governance and material events.
Among the key documents available are Current Reports on Form 8-K, where Ardent Health reports significant developments. Recent 8-K filings describe quarterly financial results, including the release of earnings for specific quarters and the use of non-GAAP measures such as Adjusted EBITDA and Adjusted EBITDAR. These filings often incorporate the related earnings press release as an exhibit, providing definitions of non-GAAP metrics, reconciliations to GAAP measures and discussions of operating metrics like admissions, surgeries and net patient service revenue per adjusted admission.
Other 8-K filings detail financing and capital structure actions. For example, Ardent Health has reported amendments to its Amended and Restated Term Loan Credit Agreement and its Amended and Restated ABL Credit Agreement, extending term loan maturities, adjusting interest rate spreads over Term SOFR and the base rate, and updating baskets for certain negative covenants. Another 8-K describes the authorization of a stock repurchase program of up to $50.0 million of the company’s common stock, including the potential use of open market purchases, privately negotiated transactions, block trades and Rule 10b5-1 plans.
Filings also cover governance and executive matters, such as leadership changes and the treatment of departures under the company’s Executive Severance Plan. References to proxy statements and severance plan documents in these filings point investors to additional information on executive compensation and severance arrangements.
On Stock Titan, these ARDT filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the substance of each filing, highlight key terms in credit agreements, clarify the implications of non-GAAP metrics and stock repurchase authorizations, and make it easier to understand how individual disclosures relate to Ardent Health’s hospital operations and financial profile.
David Raynor Byers, Senior Vice President & Chief Accounting Officer of Ardent Health, Inc. (ARDT), reported a routine disposition of common stock on 09/25/2025. The filing shows 524 shares were disposed under Code F (withholding to pay taxes upon vesting of restricted stock units) at a reported price equal to the closing stock price on 09/25/2025 of $13.19. After the withholding, Mr. Byers beneficially owns 111,791 shares directly. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Ardent Health, Inc. amended its term loan and ABL credit facilities with Bank of America and other lenders. The Term Loan Amendment refinanced outstanding term loans in full, extended the term loan maturity from August 24, 2028 to September 18, 2032, reduced the applicable interest spread by 50 basis points (from Term SOFR+2.75% to Term SOFR+2.25%, and from base rate+1.75% to base rate+1.25%), and expanded fixed-dollar negative covenant baskets. The ABL Amendment aligned certain fixed-dollar negative covenant baskets with the term loan changes but did not extend the ABL maturity or make other material changes. The full amendment texts are filed as exhibits and govern the detailed terms.
Ardent Health, Inc. operates a network of 30 acute care hospitals and approximately 280 sites of care across six states with 1,875 employed and affiliated providers as of June 30, 2025. The company uses a joint-venture model in which it is typically the majority owner and day-to-day operator, partnering with academic and not-for-profit systems to expand market presence and clinical services. EGI-AM Investments, L.L.C. owned approximately 54.0% of outstanding common stock, making EGI-AM the company’s controlling stockholder under NYSE rules. The filing discloses a table of selling stockholders showing large share blocks (for example, 77,246,499 shares representing 54.0%) and various other holders with specified share counts and percentages. The prospectus lists exhibits, underwriting and legal opinions, audit consents from Ernst & Young LLP, and a registration fee table.
Ardent Health, Inc. (NYSE: ARDT) filed an 8-K disclosing the immediate departure of David Schultz, President, Hospital Operations, effective June 16 2025. The company classified the exit as a “Qualifying Termination” under its Executive Severance Plan, making Mr. Schultz eligible for severance payments and related benefits, subject to standard plan conditions such as non-compete and non-solicitation covenants.
The filing provides no quantitative detail on payout size, claw-back triggers, or succession plans. Mr. Schultz had overseen the hospital segment, a core operating unit that drives the majority of Ardent’s revenue. Governance protocol appears to have been followed—compensation terms reference disclosures in the April 8 2025 proxy statement and the Q2 2024 10-Q exhibit that contains the Severance Plan.
Investment relevance:
- Unanticipated C-suite turnover can disrupt execution of operational initiatives, regulatory compliance, and cost-containment programs, potentially affecting near-term margin trajectory.
- Because no interim or permanent replacement was announced, investors face visibility risk on leadership continuity in hospital operations.
- Cash severance outflows could be modest relative to Ardent’s scale, but exact magnitude is not provided, limiting assessment of liquidity impact.